^
CANCER:

Genito-urinary Cancer

Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
No biomarker
Clear Cell Renal Cell Carcinoma
pembrolizumab
Sensitive
:
A2
PMLive - 5 days - (New A2)
MSI-H/dMMR
Prostate Cancer
pembrolizumab
Sensitive
:
A2
Front Oncol - 1 week - (New C4)
No biomarker
Prostate Cancer
enzalutamide capsule
Sensitive
:
A1
FDA - 2 weeks - (New A1)
FOLH1 positive
Prostate Cancer
lutetium Lu 177 vipivotide tetraxetan
Sensitive
:
A1
Canada Newswire - 2 weeks - (New A1)
SPOP mutation
Prostate Cancer
Androgen receptor inhibitor
Sensitive
:
C3
Clin Cancer Res - 2 weeks - (New C3)
No biomarker
Renal Cell Carcinoma
pembrolizumab
Sensitive
:
A1
Lancet Oncol - 3 weeks - (New B)
BRCA2 mutation
Prostate Cancer
olaparib
Sensitive
:
A1
ESMO 2022 - 3 weeks - (New C3)
BRCA1 mutation
Prostate Cancer
olaparib
Sensitive
:
A1
ESMO 2022 - 3 weeks - (New C3)
PD-L1 expression
Bladder Cancer
pembrolizumab
Sensitive
:
A2
ESMO 2022 - 3 weeks - (New C3)
PD-L1 expression
Bladder Cancer
durvalumab
Sensitive
:
C1
ESMO 2022 - 3 weeks - (New C3)
CREBBP mutation
Bladder Cancer
Immunotherapy
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
HRAS Q61
Bladder Cancer
Immunotherapy
Resistant
:
C3
ESMO 2022 - 3 weeks - (New C3)
KDM6A mutation
Urothelial Cancer
atezolizumab
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
CD3G overexpression
Renal Cell Carcinoma
nivolumab
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
BONSAI high signature
Renal Cell Carcinoma
cabozantinib tablet
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
NCAM1 overexpression
Renal Cell Carcinoma
nivolumab
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
MTOR overexpression
Renal Cell Carcinoma
nivolumab
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
CD4 underexpression
Renal Cell Carcinoma
nivolumab
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
SPOP mutation
Prostate Cancer
enzalutamide capsule + abiraterone acetate + apalutamide
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
AR wild-type
Prostate Cancer
abiraterone acetate
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
AR wild-type
Prostate Cancer
enzalutamide capsule
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
CD27 overexpression
Clear Cell Renal Cell Carcinoma
PD1 inhibitor
Resistant
:
C3
Clin Cancer Res - 3 weeks - (New C3)
FGFR3-TACC3 fusion + FGFR3 V555M
Urothelial Cancer
TYRA-300
Sensitive
:
D
ESMO 2022 - 3 weeks - (New D)
No biomarker
Renal Cell Carcinoma
nivolumab + cabozantinib tablet
Sensitive
:
A1
PD-L1 expression
Urothelial Cancer
atezolizumab
Sensitive
:
A1
No biomarker
Prostate Cancer
apalutamide
Sensitive
:
A1
No biomarker
Urothelial Cancer
avelumab
Sensitive
:
A1
No biomarker
Urothelial Cancer
sacituzumab govitecan-hziy
Sensitive
:
A1
PD-L1 expression
Renal Cell Carcinoma
avelumab + axitinib
Sensitive
:
A1
No biomarker
Prostate Cancer
histrelin acetate
Sensitive
:
A1
No biomarker
Prostate Cancer
cabazitaxel
Sensitive
:
A1
No biomarker
Renal Cell Carcinoma
avelumab + axitinib
Sensitive
:
A1
No biomarker
Renal Cell Carcinoma
bevacizumab-awwb
Sensitive
:
A1
No biomarker
Renal Cell Carcinoma
bevacizumab-bvzr
Sensitive
:
A1
No biomarker
Prostate Cancer
relugolix
Sensitive
:
A1
No biomarker
Germ Cell Tumors
dactinomycin
Sensitive
:
A1
No biomarker
Testicular Cancer
etoposide IV
Sensitive
:
A1
No biomarker
Testicular Cancer
cisplatin
Sensitive
:
A1
No biomarker
Testicular Cancer
ifosfamide
Sensitive
:
A1
No biomarker
Renal Cell Carcinoma
sorafenib
Sensitive
:
A1
No biomarker
Renal Cell Carcinoma
tivozanib
Sensitive
:
A1
No biomarker
Urothelial Cancer
mitomycin urothelial gel
Sensitive
:
A1
No biomarker
Renal Cell Carcinoma
temsirolimus
Sensitive
:
A1
No biomarker
Renal Cell Carcinoma
sunitinib
Sensitive
:
A1
No biomarker
Renal Cell Carcinoma
everolimus + lenvatinib
Sensitive
:
A1
No biomarker
Prostate Cancer
docetaxel + prednisone
Sensitive
:
A1
No biomarker
Prostate Cancer
abiraterone acetate
Sensitive
:
A1
No biomarker
Renal Cell Carcinoma
everolimus
Sensitive
:
A1
No biomarker
Prostate Cancer
degarelix
Sensitive
:
A1
PD-L1 expression
Urothelial Cancer
pembrolizumab
Sensitive
:
A1
No biomarker
Renal Cell Carcinoma
bevacizumab + pegylated interferon α -2a
Sensitive
:
A1
ATM mutation
Prostate Cancer
olaparib
Sensitive
:
A1
No biomarker
Prostate Cancer
darolutamide
Sensitive
:
A1
No biomarker
Renal Cell Carcinoma
cabozantinib tablet
Sensitive
:
A1
No biomarker
Bladder Cancer
cisplatin
Sensitive
:
A1